Slow-healing, chronic wounds have a negative impact on patient wellbeing, are challenging for clinicians to manage and are costly to the health economy (Frykberg and Banks, 2015). Woulgan is a newly available wound care gel containing the active ingredient 2% soluble beta-glucan. Beta-glucan has immunomodulating properties and has been shown to kick-start the healing of slow-healing wounds. A working group of key opinion leaders met in January 2018 to determine the potential role of Woulgan gel in slow-healing wounds, such as diabetic foot ulcers, pressure ulcers and venous leg ulcers, and to develop a decision pathway for clinical practice to support clinicians in escalating treatment promptly to avoid unnecessary impact on patient wellbeing and costs. The group’s consensus recommendations on appropriate use are presented here.